Status:
UNKNOWN
Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer
Lead Sponsor:
Xijing Hospital
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Gemcitabine
Eligibility:
FEMALE
18-70 years
Brief Summary
The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer ...
Eligibility Criteria
Inclusion
- Histologically Confirmed Metastatic, or Recurrent Breast Cancer
- Age over 18 Years
- ECOG Performance Status 0-2
- Premenopausal or Postmenopausal Breast Cancer Patients With Measurable or Non-Measurable Lesions, Who Are Candidates for Chemotherapy
- Life Expectancy ≥ 3 Months
- Patients May Have Received Prior Neoadjuvant or Adjuvant Taxane Regimen as Long as it Has Been 12 Months Since Completion of Regimen.
- Patients Either May or May Not Have a Prior Anthracycline Containing Regimen.
- Prior Hormonal Therapy as a Treatment of Metastatic Disease is Allowed. But Antitumoral Hormonal Therapy Must be Terminated Prior to Enrollment(up to the Date of Randomization)
- Prior Radiation Therapy Allowed as Long as \< 25% of the Bone Marrow Has Been Treated,and the Patients Must Have Recovered From the Acute Toxic Effects of the Treatment Prior to Study Enrollment.Prior Radiation to the Whole Pelvis is Not Allowed. Prior Radiotherapy Must be Completed 4 Weeks Before Study Entry.
- Adequate Bone Marrow Function (≥ ANC 1,500/ul, ≥ Platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl)
- Adequate Renal Function (≤ Serum Creatinine 1.5 mg/dl or CCr ≥ 50 ml/Min)
- Adequate Liver Function (≤ Serum Bilirubin 1.5 mg/dl, ≤ AST/ALT x 3 Upper Normal Limit)
- No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer
- Written Informed consent
Exclusion
- Serious Uncontrolled Intercurrent Infections
- Serious Intercurrent Medical or Psychiatric Illness, Including Active Cardiac Disease
- Pregnancy or Breast Feeding
- Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence)
- Documented Parenchymal or Leptomeningeal Brain Metastasis
- Peripheral Neuropathy ≥ Grade 2
- Prior Treatment With Gemcitabine Will Not be Allowed.
- HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
267 Patients enrolled
Trial Details
Trial ID
NCT02188693
Start Date
July 1 2014
End Date
December 1 2017
Last Update
July 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital ， Fourth Military Medical University
Xi'an, Shaanxi, China, 710032